HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multiple tissue response modifiers to promote angiogenesis and prevent the foreign body reaction around subcutaneous implants.

Abstract
Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl alcohol) hydrogel composite coatings have been shown to prevent the foreign body reaction (FBR) to subcutaneous implants in small and large animal models. Such coatings were developed to extend the lifetime of implantable biosensors. However, long-term exposure of tissue to low levels of dexamethasone results in a reduction in blood vessel density due to the anti-angiogenic effect of dexamethasone. This mild effect, while not threatening to the subject's health, may interfere with analyte detection and the sensor response time over the long-term. The present work is focused on the development of coatings that deliver combinations of three tissue response modifiers (TRMs): dexamethasone, VEGF (vascular endothelial growth factor) and PDGF (platelet derived growth factor). Dexamethasone, VEGF and PDGF prevent the FBR, increase angiogenesis and promote blood vessel maturation (which increases blood flow), respectively. To minimize any potential interference among these three TRMs (for example, PDGF increases fibrosis), the relative doses of dexamethasone, VEGF and PDGF were adjusted. It was determined that: a) all three TRMs are required for maximum promotion of angiogenesis, blood vessel maturation and prevention of the FBR; b) VEGF has to be administered at higher doses than PDGF; c) an increase in dexamethasone dosing must be accompanied by a proportional increase in growth factor dosing; and d) modification of the TRM ratio can achieve a constant capillary density throughout the implantation period which is important for applications such as biosensors to maintain sensitivity and a stable sensor baseline. Moreover, an osmosis-driven process for encapsulation of proteins in PLGA microspheres that showed low burst release was developed.
AuthorsMichail Kastellorizios, Fotios Papadimitrakopoulos, Diane J Burgess
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 214 Pg. 103-11 (Sep 28 2015) ISSN: 1873-4995 [Electronic] Netherlands
PMID26216396 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Drug Implants
  • Hydrogels
  • Platelet-Derived Growth Factor
  • Vascular Endothelial Growth Factor A
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Dexamethasone
  • Polyvinyl Alcohol
Topics
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Animals
  • Chemistry, Pharmaceutical
  • Dexamethasone (administration & dosage, therapeutic use)
  • Drug Implants
  • Foreign-Body Reaction (prevention & control)
  • Hydrogels
  • Lactic Acid
  • Male
  • Microspheres
  • Neovascularization, Pathologic (prevention & control)
  • Particle Size
  • Platelet-Derived Growth Factor (pharmacology)
  • Polyglycolic Acid
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyvinyl Alcohol
  • Rats
  • Rats, Sprague-Dawley
  • Subcutaneous Tissue
  • Vascular Endothelial Growth Factor A (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: